16 stories found
The US Food and Drug Administration has extended its review period for Exelixis' zanzalintinib, a treatment for colorectal cancer, by three months. The delay caused Exelixis stock to fall as investors awaited further regulatory clarity.
Several companies, including Exelixis, Sionna Therapeutics, N-able, Workday, and UWM Holdings, are facing securities fraud investigations. Investors have the opportunity to join these lawsuits led by SBS Law.
An analysis explores whether Exelixis, Inc. (EXEL) is an attractive investment opportunity among lesser-known stocks.
Exelixis stock has reached a new high, driven by growing sales figures and increased institutional investment.
Exelixis has provided a December PDUFA timeline for its ZANZA CRC filing and announced an additional $750 million share buyback authorization.
Exelixis, a cash-generating biotech company, is being highlighted as a stock that warrants closer examination by investors for potential opportunities in 2026.
Major owners of Exelixis are expanding their ownership percentages as the pharmaceutical company navigates significant operational and strategic shifts.
SiTime has outlined its Q3 revenue forecast, Arcutis has raised its 2026 net revenue guidance, and Exelixis has lowered its 2026 revenue guidance midpoint while detailing launch plans for ZANZA CRC.
A new analyst from Truist has provided insights into Exelixis (EXEL) and its next-generation cancer drug, offering a fresh perspective on the company's pharmaceutical developments.
Leopold Aschenbrenner has disclosed new and updated positions on several stocks, showing a bearish stance on companies like Galaxy Digital, Kilroy Realty Corporation, and Lumentum Holdings. Conversely, Aschenbrenner remains bullish on ProPetro Holding Corp. and Babcock & Wilcox Enterprises, Inc., while also revealing a new bet on WhiteFiber, Inc.
RBC Capital has adjusted its price target for Exelixis (EXEL) stock downwards to $43.
Activist investors have taken action involving Exelixis, Valaris, and three other companies' stocks.
Exelixis presented highlights from its Q2 earnings call, outlining its financial results and progress in its pharmaceutical development.
Exelixis shares dropped following the final analysis of its zanzalintinib phase 3 trial data, which reportedly disappointed investors.
TD Cowen analysts have identified pipeline growth opportunities that are expected to support the positive outlook for Exelixis, Inc. (EXEL).
An analysis outlines three reasons why Exelixis stock is projected to deliver market-beating returns over the next decade, focusing on its investment potential.